2-(2-羟甲基)-5-硝基苯基)乙醇 | 186390-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-羟甲基)-5-硝基苯基)乙醇
• 英文名称: 2-(2-Hydroxymethyl-5-nitro-phenyl)-ethanol
• 英文别名: 2-(2-(Hydroxymethyl)-5-nitrophenyl)ethanol；2-[2-(hydroxymethyl)-5-nitrophenyl]ethanol
• CAS: 186390-74-9
• 化学式: C₉H₁₁NO₄
• mdl: MFCD03840420
• 分子量: 197.191
• InChiKey: SYBKBPXOVQYFFA-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81 °C
• 沸点：
  416.4±35.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(2-羟甲基)-5-硝基苯基)乙醇 在 氨 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， -78.0~24.0 ℃ 、827.37 kPa 条件下， 反应 60.5h， 生成 1,2,3,4-四氢-6-硝基异喹啉
  参考文献：
  名称：

  Synthesis of 1,2,3,4-Tetrahydroisoquinolines Containing Electron-Withdrawing Groups

  摘要：

  DOI：

  10.1021/jo972184e
• 作为产物：
  描述：

  2-氯-4-硝基苯甲酸 在 sodium hydroxide 、 sodium tetrahydroborate 、 三氟化硼乙醚 、 copper(I) bromide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 25.0h， 生成 2-(2-羟甲基)-5-硝基苯基)乙醇
  参考文献：
  名称：

  Synthesis of 1,2,3,4-Tetrahydroisoquinolines Containing Electron-Withdrawing Groups

  摘要：

  DOI：

  10.1021/jo972184e
• 作为试剂：
  描述：

  4-硝基羧基邻苯二甲酸 、 乙酸酐 在 2-(2-羟甲基)-5-硝基苯基)乙醇 作用下， 以 甲苯 为溶剂， 反应 5.0h， 以to yield 6-nitro-isochroman-1,3-dione (compound (10) in Scheme 2) as a yellow solid (10.51 g, 88%)的产率得到2-(2-羟甲基)-5-硝基苯基)乙醇
  参考文献：
  名称：

  Apo B-secretion/MTP inhibitory amides

  摘要：

  本发明涉及式(I)化合物或其立体异构体、药学上可接受的盐和水合物。这些化合物是Apo B/MTP抑制剂，可用于治疗各种疾病和症状，如动脉粥样硬化、胰腺炎、肥胖症、高胆固醇血症、高甘油三酯血症、高脂血症和糖尿病。该发明的化合物还可与其他药物剂合用，包括胆固醇生物合成抑制剂和胆固醇吸收抑制剂，特别是HMG-CoA还原酶抑制剂和HMG-CoA合成酶抑制剂；HMG-CoA还原酶基因表达抑制剂；CETP抑制剂；胆汁酸结合树脂；纤维酸类；胆固醇吸收抑制剂；ACAT抑制剂、角鲨烷合酶抑制剂、离子交换树脂、抗氧化剂和烟酸。本发明还涉及中间体和有用于制备式(I)化合物的过程。

  公开号：

  US06121283A1

文献信息

• Dicyclopentyl azodicarboxylate (DCpAD): A new alternative azo-reagent for the Mitsunobu reaction
  作者：Jian Hai Yang、Li Yan Dai、Xiao Zhong Wang、Ying Qi Chen

  DOI：10.1016/j.cclet.2011.03.017

  日期：2011.9

  Dicyclopentyl azodicarboxylate is introduced as a new azo-reagent which can be conveniently prepared in two steps and be used in the Mitsunobu reaction. Though there are no distinct difference of reactivity between DCpAD and DEAD, the former is a more preferable azo-reagent for its stability.

  引入偶氮二羧酸二环戊酯作为一种新型的偶氮试剂，可以方便地分两步制备并用于Mitsunobu反应。尽管DCpAD和DEAD之间没有明显的反应性差异，但是前者由于其稳定性是更优选的偶氮试剂。
• Oxazolidinones having a benzannulated 6- or 7-membered heterocycle
  申请人：——

  公开号：US20020133021A1

  公开（公告）日：2002-09-19

  The present invention provides oxazolidinones having a benzannelated 6- or 7-membered heterocycle as antibacterial agents.

  本发明提供了具有苯并环的6-或7-员杂环的噁唑烷酮类作为抗菌剂。
• Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion
  申请人：PFIZER INC.

  公开号：EP1181954A3

  公开（公告）日：2002-08-21

  Compositions comprising a lipid lowering agent selected from cholesterol biosynthesis inhibitors, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, and niacin; and an inhibitor of microsomal triglyceride transfer protein for treating atherosclerosis, obesity and related diseases.

  组成物包括从胆固醇生物合成抑制剂、胆酸螯合剂、纤维酸、胆固醇吸收抑制剂和烟酸中选择的一种降脂剂，以及用于治疗动脉粥样硬化、肥胖症和相关疾病的微粒体甘油三酯转移蛋白抑制剂。
• Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide
  申请人：Pfizer INc.

  公开号：US05919795A1

  公开（公告）日：1999-07-06

  Compounds of formula (I), ##STR1## wherin X is CH.sub.2, CO, CS or SO.sub.2 ; Y is selected from: a direct link, aliphatic hydrocarbylene radicals having up to 20 carbon atoms, which radical may be mono-substituted by hydroxy, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)acyl, (C.sub.1 -C.sub.10)acyloxy, or (C.sub.6 -C.sub.10)aryl, NH, and O, provided that if X is CH.sub.2,Y is a direct link; Z is selected from the following groups: (1) H, halo, cyano, (2) hydroxy, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)a1kylthio, (C.sub.1 -C.sub.10)acyl, thiophenylcaronyl (C.sub.1 -C.sub.10)alkoxycarbonyl, (3) (C.sub.1 -C.sub.10)aklkyammo, di(C.sub.1 -C.sub.10)alylamino, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkylamino, provided that Y is not O or NH, (4) unsubstituted vinyl, (C.sub.6 -C.sub.10)aryl, (C.sub.3 -C.sub.8)cycloalkyl and fused benz derivatives thereof, (C.sub.7 -C.sub.10)polycycloalkyl, (C.sub.4 -C.sub.8)cycloalkenyl, (C.sub.7 -C.sub.10)polycycloalkenyl, (5) (C.sub.6 -C.sub.10)aryloxy, (C.sub.6 -C.sub.10)aryltio, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkoxy, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkylthio, (C.sub.3 -C.sub.8)cycloalkyloxy, (C.sub.4 -C.sub.8)cycloalkenyloxy, (6) heterocyclyl sclected from the group consisting of monocyclic radicals and fused polycycuic radicals, wherein said radicals contain a total of from 5 to 14 ring atoms, wherein said radicals contain a total of from 1 to 4 ring heteroatoms independently selocted from oxygen, nitrogen, and sulfur, and wherein the individual rings of said radicals may be independendy satated, partally unsaturated, or aromatic, provided that if X is CH.sub.2, Z is H or is selected from groups (4) and (6), wherein, when Z contains one or more rings, said rings may each independently bear 0 to 4 substituents independently selected from halo, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl phenoxy, phenylthio, halophenylthio, benzyl, benzyloxy, (C.sub.1 -C.sub.10)alkyl, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)alkoxycarbonyl, (C.sub.1 -C.sub.10)althyltio, (C.sub.1 -C.sub.10)altylamino, (C.sub.1 -C.sub.10)alkylaminocarbonyl, di(C.sub.1 -C.sub.10)alkylamino, di(C.sub.1 -C.sub.10)alkylaminocarbonyl, di(C.sub.1 -C.sub.10)alkyo(C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.3)perfluoroalkyl, (C.sub.1 -C.sub.3)perfluoroalkoxy, (C.sub.1 -C.sub.10)acyl, (C.sub.1 -C.sub.10)acyloxy, (C.sub.1 -C.sub.10)acyloxy(C.sub.1 -C.sub.10)alkyl, and pyrrolidinyl; and pharmaceutically acceptable salts thereof.

  化合物的化学式（I），其中X为CH.sub.2，CO，CS或SO.sub.2；Y从以下选项中选择：直接连接，具有多达20个碳原子的脂肪烃基，该基团可以被羟基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）酰基，（C.sub.1-C.sub.10）酰氧基或（C.sub.6-C.sub.10）芳基单取代，NH和O取代，前提是如果X为CH.sub.2，则Y为直接连接；Z从以下组中选择：（1）H，卤素，氰基，（2）羟基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）烷基硫基，（C.sub.1-C.sub.10）酰基，硫代苯甲酰（C.sub.1-C.sub.10）烷氧羰基，（3）（C.sub.1-C.sub.10）烷基氨基，二（C.sub.1-C.sub.10）烷基氨基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷基氨基，前提是Y不是O或NH，（4）未取代的乙烯基，（C.sub.6-C.sub.10）芳基，（C.sub.3-C.sub.8）环烷基及其融合苯衍生物，（C.sub.7-C.sub.10）多环烷基，（C.sub.4-C.sub.8）环烯基，（C.sub.7-C.sub.10）多环烯基，（5）（C.sub.6-C.sub.10）芳氧基，（C.sub.6-C.sub.10）芳硫基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷氧基，（C.sub.6-C.sub.10）芳基（C.sub.1-C.sub.10）烷基硫基，（C.sub.3-C.sub.8）环烷氧基，（C.sub.4-C.sub.8）环烯氧基，（6）从单环基团和融合多环基团中选择的杂环基，其中所述基团包含总共5至14个环原子，其中所述基团包含总共1至4个环杂原子，独立选择自氧，氮和硫，并且所述基团的各个环可以独立饱和，部分不饱和或芳香，前提是如果X为CH.sub.2，则Z为H或从组（4）和（6）中选择，其中，当Z含有一个或多个环时，所述环可以各自独立地携带0至4个取代基，独立选择自卤素，羟基，氰基，硝基，氧代硫代，氨基磺酰基，苯基苯氧基，苯基硫基，卤苯基硫基，苄基，苄氧基，（C.sub.1-C.sub.10）烷基，（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.10）烷氧羰基，（C.sub.1-C.sub.10）烷硫基，（C.sub.1-C.sub.10）烷基氨基，（C.sub.1-C.sub.10）烷基氨基羰基，二（C.sub.1-C.sub.10）烷基氨基，二（C.sub.1-C.sub.10）烷基氨基羰基，二（C.sub.1-C.sub.10）烷氧（C.sub.1-C.sub.10）烷氧基，（C.sub.1-C.sub.3）全氟烷基，（C.sub.1-C.sub.3）全氟烷氧基，（C.sub.1-C.sub.10）酰基，（C.sub.1-C.sub.10）酰氧基，（C.sub.1-C.sub.10）酰氧（C.sub.1-C.sub.10）烷基和吡咯啉基；及其药学上可接受的盐。
• Di-p-nitrobenzyl azodicarboxylate (DNAD): an alternative azo-reagent for the Mitsunobu reaction
  作者：Jianhai Yang、Liyan Dai、Xiaozhong Wang、Yingqi Chen

  DOI：10.1016/j.tet.2010.12.036

  日期：2011.2

  Di-p-nitrobenzyl azodicarboxylate is prepared in 83.6% yield in two steps as a bright yellow solid, which can be used as an azo-reagent in the Mitsunobu reaction. When a chiral secondary alcohol was used, sufficient configurational inversion of alcohol occurred under Mitsunobu conditions. That the hydrazine produced from DNAD is semisoluble in some solvents such as THF and CH2Cl2 makes it separated

  分两步制备呈亮黄色固体的二对硝基苄基偶氮二羧酸酯，产率为83.6％，可以用作Mitsunobu反应中的偶氮试剂。当使用手性仲醇时，在Mitsunobu条件下发生足够的构型醇转化。由DNAD产生的肼在某些溶剂（如THF和CH 2 Cl 2）中可半溶，因此仅通过过滤即可将其轻松从反应混合物中分离出来。然后可以将回收的肼化合物重新暴露于氧化剂以产生DNAD。由于DNAD在环境温度下比DIAD更稳定并且易于分离，因此它是Mitsunobu反应的良好替代偶氮试剂。